Zydus Cadila gets final approval from USFDA for Atazanavir Capsules

05 Jun 2020 Evaluate
Zydus Cadila has received final approval from the US Food and Drug Administration (USFDA) to market Atazanavir Capsules (US RLD: Reyata Capsules) in the strengths of 150 mg, 200 mg and 300 mg. Atanazavir, an antiretroviral drug, is used to treat infection of the Human Immunodeficiency Virus (HIV). It is used in combination with other antiretroviral drugs to treat HIV-1 infection.

The drug will be manufactured at the group’s manufacturing facility at SEZ, Anmedabad. The group now has 291 approvals and has so far filed over 390 ANDAs since the commencement of the filing process in FY 2003-04. 

Cadila Healthcare is an India-based pharmaceutical company. The company's subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.


Zydus Lifesciences Share Price

948.20 -2.75 (-0.29%)
26-Apr-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1504.25
Dr. Reddys Lab 6263.70
Cipla 1406.25
Zydus Lifesciences 948.20
Lupin 1615.85
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.